Expert Panel to Discuss Growing Global Impact and Innovative New Solutions to Emerging Diseases Breakfast Sponsored by Bioaccelerate Holdings Inc. to be Held at Milken Institute Global Conference NEW YORK, April 11 /PRNewswire-FirstCall/ -- Bioaccelerate Holdings Inc. (OTC:BACL) (BULLETIN BOARD: BACL) announced today a distinguished panel of experts to discuss the global impact and innovative new solutions to the treatment of neglected diseases at its Company-sponsored breakfast meeting at the Milken Institute Global Conference. The invitation-only breakfast will take place on April 19, 2005, from 6:45 a.m. to 7:45 a.m. in the Brighton Room in the Executive Center of the Beverly Hilton Hotel in Los Angeles, CA. "Infectious diseases pose an urgent global crisis-threatening the economic survival of the poorest countries and the growth and development of many more," stated Bruce Murdoch, Acting Chief Executive Officer of Candid Pharmaceuticals, a Bioaccelerate subsidiary focused on emerging diseases. "Broad-based efforts by organizations like the World Health Organization (WHO) should be commended and supported through international effort by governments, academic institutions and the healthcare industry." "Since the 1970s, at least 30 new infectious diseases have emerged for which effective treatments either do not exist or do not always find their ways to patients. Studies on the effect of AIDS, malaria and tuberculosis indicate that the social structures and functioning of societies increasingly affected by these diseases are being systematically eroded," commented Frank Armstrong, M.D., Chief Operating Officer of Bioaccelerate. "The very concept of sustainable global economic growth may be at stake. For that reason, this panel topic strongly echoes other key themes that will be discussed throughout the conference-health, security, trade and globalization." The panelists include: * Greg Simon, President, FasterCures / The Center for Accelerating Medical Solutions Mr. Simon will moderate this breakfast panel, highlighting the urgent need for a more focused US and international policy and action plan for dealing with the dire economic impact and immeasurable human toll from the uncontrolled spread of deadly infectious diseases. Mr. Simon will discuss how, increasingly, epidemics such as SARS have emerged as one of greatest risk factors threatening the stability of an interdependent international economic community and how global companies need to address this threat within their strategic business decisions. Prior to joining FasterCures in July 2003, Mr. Simon was CEO of Simon Strategies/Mindbeam, a consulting firm focusing on clients in biotechnology, health care, technology and information technology among other issues. From 1993 to 1997, he was Chief Domestic Policy Advisor to Vice President Al Gore specifically on economic, science and technology issues. In that capacity, he oversaw a number of initiatives, including the programs of the National Institutes of Health, National Cancer Institute, Food and Drug Administration (FDA), the Human Genome Project, and the development of the regulatory framework for biotechnology products. * Michael J. Ryan, MD, MPH, MFPHM, Coordinator of WHO's Global Alert and Response Unit Dr. Ryan will provide a "view from the front line" in fighting emerging diseases. His remarks will focus on how the WHO is working with partners to put into place an effective global alert and response system, the need for an investment in building national capacities to detect and respond to these threats and what the private sector can do it terms of product development and corporate support. This presentation will draw deeply from his experiences in dealing with over 50 international responses over the past three years. Dr. Ryan has worked with WHO since 1996, when WHO established a unit to respond to emerging and epidemic disease threats. During his time at WHO, Dr. Ryan has led numerous outbreak response teams to the field for diseases such as Ebola, meningitis, cholera, bacillary dysentery, Crimean-Congo hemorrhagic fever, rift valley fever and relapsing fever. He became Coordinator of WHO's Global Alert and Response Team in 2001 and has put into place WHO's epidemic intelligence, verification and response mechanisms, as well as the Global Outbreak Alert and Response Network (GOARN), which have been utilized in recent outbreaks such as SARS and Influenza. He was appointed Director of Alert and Response Operations in June 2004 with responsibility for the further development and implementation of the WHO-wide response to epidemics and other public health emergencies of international concern requiring immediate operational response and has WHO's Strategic Health Operations Centre under his responsibility. He completed Medical Training at University College Galway and his Masters in Public Health at University College Dublin followed by specialist training in public health/communicable disease at the UK Communicable Disease Surveillance Centre in London. * Frank Armstrong, M.D., Chief Operating Officer, Bioaccelerate Dr. Armstrong will discuss how Bioaccelerate's business model helps streamline the process of developing a drugs for a variety of diseases, including infectious diseases, and bringing needed treatments to millions of people worldwide. Dr. Armstrong joined Bioaccelerate in January 2005. Previously, he was CEO of Provensis, a BTG Company, and CEO of Phoqus, a private drug delivery company. Earlier, he was Head of Worldwide Product Development for Bayer AG, and Senior Vice President Medical Research and Communications Group, Zeneca Pharmaceuticals (now AstraZeneca), based in the US. Dr. Armstrong holds degrees from the University of Edinburgh in Biochemistry and Medicine and is a Fellow of the Royal College of Physicians (Edinburgh) and a Fellow of the Faculty of Pharmaceutical Medicine in the UK. ABOUT THE WORLD HEALTH ORGANIZATION The WHO is the United Nations specialized agency for health. It was established on 7 April 1948. WHO's objective, as set out in its Constitution, is the attainment by all peoples of the highest possible level of health. Health is defined in WHO's Constitution as a state of complete physical, mental and social well being and not merely the absence of disease or infirmity. Additional information on The World Health Organization is available at http://www.who.org/. ABOUT FASTERCURES / THE CENTER FOR ACCELERATING MEDICAL SOLUTIONS FasterCures is an "action tank" committed to building faster tracks to find tomorrow's cures today. Its mission is to clear the path between an idea for treatment and getting a treatment to the patient. Additional information is available at http://www.fastercures.org/. ABOUT THE MILKEN INSTITUTE GLOBAL CONFERENCE This year's conference, "Building a Prosperous Future," will examine such issues as biotechnology and the promise of medical breakthroughs; the global investment climate; and the latest economic developments in Europe, Asia, Latin America and the US. Among confirmed speakers at the conference are former Vice President Al Gore; Rupert Murdoch, Chairman and CEO, News Corporation; Terry Semel, Chairman and CEO, Yahoo!; Charlene Barshefsky, former U.S. Trade Representative; Mel Karmazin, CEO, SIRIUS Satellite Radio; Steve Forbes, President and CEO, Forbes; William Haseltine, former CEO, Human Genome Sciences; Jonathan Miller, Chairman and CEO, AOL; Mike Milken, Chairman of FasterCures and the Milken Institute; Steve Wynn, President and CEO, Wynn Resorts; Sam Zell, Chairman, Equity Group Investments; and more than 300 others. For complete information about the 2005 Global Conference, go to: http://www.milkeninstitute.org/gc2005. ABOUT BIOACCELERATE HOLDINGS INC. Bioaccelerate Holdings Inc. (BACL.OB) is a pharmaceutical development organization ("PDO"). It conducts its business directly and through its subsidiaries. The company holds majority equity interests in 10 biopharmaceutical companies, three of which are public, and holds minority interests in four biopharmaceutical companies, two of which are public. The company also holds a minority equity interest in a public nanotechnology company. Bioaccelerate's strategy relies on its development network for research, clinical development and project management to guide early-stage compounds from the discovery process through to Phase II/III development where incremental value can be created. Bioaccelerate Holdings is listed on the Over-The-Counter Bulletin Board under the symbol "BACL.OB." For more information on Bioaccelerate, visit the Company's website at http://www.bioaccelerate.com/. CONTACT: Bioaccelerate Holdings Inc. Christopher O'Toole Senior Vice President 212-332-4387 Matthew Haines (Investors) Vice President Noonan Russo 212-845-4235 Emily Poe (Media) Vice President Noonan Russo 212-845-4266 DATASOURCE: Bioaccelerate Holdings Inc. CONTACT: Christopher O'Toole, Senior Vice President of Bioaccelerate Holdings Inc., +1-212-332-4387; or Matthew Haines (Investors), Vice President of Noonan Russo, +1-212-845-4235; or Emily Poe (Media), Vice President of Noonan Russo, +1-212-845-4266 Web site: http://www.bioaccelerate.com/

Copyright